5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.
Yingjie Du, Xiangting Zhao, Quan Chen, Yafan Bai, Yue Zhang, Ruirong Chen, Guyan Wang
Chinese medical journal September 15, 2026 DOI: 10.1097/cm9.0000000000004350 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled preclinical experiment in rodents Peer reviewed |
|---|---|
| Population | Male C57BL/6J mice undergoing auditory-cue fear conditioning |
| Interventions | Psilocybin Ketanserin MDL100907 |
| Dose | 2.5 mg/kg, intraperitoneal |
| Duration | Fear conditioning 2 days before psilocybin; extinction training 30 min after injection; extinction testing 24 h later; tissue collected 1.5 h after behavioral testing |
| Measures | freezing response, Western blotting, enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining for doublecortin-positive cells |
| Topics | Psilocybin Neuroplasticity Serotonin |
| Keywords | Fear extinction Hallucinogenic effects Medial prefrontal cortex Receptor, serotonin, 5-ht2a Stress disorders, post-traumatic |
| Key findings | Psilocybin facilitated fear extinction and increased BDNF and doublecortin-positive neurons in fear-conditioned mice even when the 5-HT2A receptor was blocked by ketanserin or MDL100907, indicating these effects are not dependent on 5-HT2A receptor activation. The authors argue this supports dissociating psilocybin's therapeutic effects from its hallucinogenic effects. |
Abstract
Psilocybin facilitates fear extinction in rodents, but its clinical utility is hampered by 5-hydroxytryptamine (5-HT) 2A-receptor-mediated hallucinogenic effects. This study aimed to explore whether 5-HT2A receptor is obligatory for psilocybin's fear extinction and neuroplasticity effect. Male C57BL/6J mice underwent auditory-cue fear conditioning. Ketanserin (5-HT2A/2C antagonist) or MDL100907 (selective 5-HT2A antagonist) was administered 30 min before a single psilocybin (2.5 mg/kg, intraperitoneal) or vehicle injection. Mice were fear-conditioned 2 days before psilocybin administration, extinction training commenced 30 min after the psilocybin injection, and extinction testing was performed 24 h later. The mice were euthanized 1.5 h after behavioral testing in the MDL100907 antagonism experiment, and hippocampal and medial prefrontal cortex (mPFC) tissues were collected. Western blotting and enzyme-linked immunosorbent assay (ELISA) were used to detect brain-derived neurotrophic factor (BDNF) protein expression. Immunofluorescence staining was used to assess the number of doublecortin-positive cells in the hippocampal dentate gyrus (DG). In extinction testing, mice that received psilocybin combined with either ketanserin or MDL100907 still exhibited a significantly lower freezing response than those treated with antagonist alone. MDL100907 pretreatment failed to block the psilocybin-evoked upregulation of BDNF in both hippocampus and mPFC. Likewise, the increase in doublecortin (DCX)-positive newborn neurons in the DG induced by psilocybin remained intact after MDL100907 blockade. The effects of psilocybin in facilitating fear extinction and increasing neuroplasticity in fear-conditioned mice are not dependent on 5-HT2A receptor activation, which supports that its therapeutic and hallucinogenic effects can be dissociated.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
Psilocybin facilitated fear extinction and increased BDNF and doublecortin-positive neurons even when the 5-HT2A receptor was blocked, indicating these effects are not dependent on 5-HT2A receptor activation.
Synthesized
-
State of the evidence: Psilocybin Supports
Psilocybin facilitated fear extinction and increased BDNF and doublecortin-positive neurons even when the 5-HT2A receptor was blocked, indicating these effects are not dependent on 5-HT2A activation.
Synthesized
Comparable studies
Other preclinical and animal studies on neuroplasticity, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| Psychedelics promote plasticity by directly binding to BDNF receptor TrkB Mice | 2023 | Experimental study | |
| Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning Mice | 2013 | Experimental study | |
| The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro Progenitor cells from subventricular and subgranular zones of adult mice brains | 2017 | In vitro experimental study | |
| N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo Mice | 2020 | In vitro and in vivo experimental study |
Citations in the library
Cites 38
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 33 more in the library